Abstract 362P
Background
Continuity of care is an important domain of provision of Palliative services. Round the clock Consultation liaison services are provided to all registered Patients (through an on-call number manned by the Resident on call). The Investigator's phone number is bieng provided upon Patient request. Advice regarding symptomatic management (including titration of analgesia), counseling regarding goals of care and opportunity to facilitate a liaison with the Patient's Local physician are bieng provided via telephonic consult. Text messages also form a frequent means of providing important treatment related information.
Methods
29 patients who had contacted this Resident during a period extending from November 2017 to May 2019 were invited to take part in an Investigator initiated Telephonic survey.
Results
11 respondents who were also primary caregivers agreed to participate. The remainder either were unreachable or declined to participate. 5/11 respondents had contacted the on call number while 7/11 had contacted the Investigator's number more than twice. 4/7 were satisfied with the response that they received on the on call number. 2 out of 10 respondents had used the number facilitating a liaison between the Resident and Local Physician. There was unanimous agreement on the feasibility and appropriateness of the on call liaison for provision of Bereavement services. There was consensus that the gender of the Resident did not affect Patient preferences. All respondents agreed that the text message had been an important means of disseminating information. Difficult to control pain was identified as the leading indication for seeking a Telephonic liaison. 3/11 respondents opined that the on-call number should be more accessible. 5/7 respondents agreed that they could have been provided better end of life care. Pain, reduced oral intake and constipation were identified as symptoms that caused the maximum amount of concern during the terminal phase of decline. Two caregivers used the opportunity to air grievances about quality of patient care services that they were provided.
Conclusions
Telephonic liaison services have the potential to act as an effective mode of delivery of palliative (including end of life care) services.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dr. Rahul D. Arora, Senior Resident, Dept. of Palliative Medicine, All India Institute of Medical Scinces, New Delhi, India.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract